Blanchard-Rohner, G;
Sanchez, C;
Andre, MC;
Bressieux-Degueldre, S;
Grazioli, S;
Perez, M-H;
Wütz, D;
Schöbi, N;
Welzel, T;
Atkinson, A;
et al.
Blanchard-Rohner, G; Sanchez, C; Andre, MC; Bressieux-Degueldre, S; Grazioli, S; Perez, M-H; Wütz, D; Schöbi, N; Welzel, T; Atkinson, A; Schlapbach, LJ; Bielicki, JA; Trück, J; Swissped RECOVERY Trial Group
(2024)
COVID-19 Vaccine Acceptance Among Parents of Children With Multisystem Inflammatory Syndrome in Children.
Pediatr Infect Dis J, 43 (4).
pp. 361-364.
ISSN 1532-0987
https://doi.org/10.1097/INF.0000000000004206
SGUL Authors: Bielicki, Julia Anna
|
PDF
Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (345kB) | Preview |
|
![]() |
Microsoft Word (.docx) (Supplemental Digital Content 1)
Supplemental Material
Download (14kB) |
|
![]() |
Microsoft Word (.docx) (Supplemental Digital Content 2)
Supplemental Material
Download (40kB) |
|
![]() |
Microsoft Word (.docx) (Supplemental Digital Content 3)
Supplemental Material
Download (29kB) |
|
|
PDF (Supplemental Digital Content 4)
Supplemental Material
Download (94kB) | Preview |
|
![]() |
Microsoft Word (.docx) (Supplemental Digital Content 5)
Supplemental Material
Download (89kB) |
Abstract
Data on COVID-19 vaccine acceptability among parents of children with multisystem inflammatory syndrome (MIS-C) are limited. In this cohort of children with MIS-C, enrolled in the Swissped RECOVERY trial (NCT04826588), comparing intravenous immunoglobulins or methylprednisolone, who, in accordance with Swiss guidelines, were recommended for SARS-CoV-2 vaccination, 65% (73/112) of parents reported being vaccinated against SARS-CoV-2 before the MIS-C, while 70% were vaccinated after the MIS-C episode of their child. None of the children were vaccinated before the occurrence of the MIS-C, and only 9% (5/56) received the COVID-19 vaccine after the MIS-C. The predominant barriers to COVID-19 vaccination were concerns over potential side effects and insufficient support from their doctors. This emphasizes the crucial role of health care providers in promoting COVID-19 vaccination among children.
Item Type: | Article | ||||||||
---|---|---|---|---|---|---|---|---|---|
Additional Information: | Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. | ||||||||
Keywords: | Swissped RECOVERY Trial Group, 1114 Paediatrics and Reproductive Medicine, 1117 Public Health and Health Services, Pediatrics | ||||||||
SGUL Research Institute / Research Centre: | Academic Structure > Infection and Immunity Research Institute (INII) | ||||||||
Journal or Publication Title: | Pediatr Infect Dis J | ||||||||
ISSN: | 1532-0987 | ||||||||
Language: | eng | ||||||||
Dates: |
|
||||||||
Publisher License: | Creative Commons: Attribution-Noncommercial-No Derivative Works 4.0 | ||||||||
PubMed ID: | 38241661 | ||||||||
Go to PubMed abstract | |||||||||
URI: | https://openaccess.sgul.ac.uk/id/eprint/116161 | ||||||||
Publisher's version: | https://doi.org/10.1097/INF.0000000000004206 |
Statistics
Actions (login required)
![]() |
Edit Item |